Only Sjögren's syndrome Phase 2 trial to meet the primary endpoint in both patient population types Patients with moderate-to-severe systemic disease activity (ESSDAI score =5) treated
Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types Patients with moderate-to-severe systemic disease activity treated with. | May 31, 2023